TEDCO Invests in Simmbion

Nonadherence to therapy in chronic disease leads to poor outcomes and high cost. It is estimated that the rate of adherence to chronic medications is only in the range of 50%, which is responsible for half of all treatment failures and up to 25% of US hospitalizations each year. Because of this reality, Simmbion, LLC, located in Baltimore, Md., is working to develop a long-term cellular factory approach for the delivery biologics similar to insulin and GLP-1 to hopefully deliver safer treatments and reduce the cost and time of care. This synthetic cell technology possesses features such as being disease-agnostic, tunable and universally immune-compatible and requires only minimal cold-chain logistics.